A landmark RCT is changing the conversation around alcohol use disorder
The numbers that stopped addiction specialists mid-sentence
The most consequential GLP-1 study of 2026 didn’t emerge from an obesity or diabetes conference. Instead, it came from the halls of Mental Health Center Copenhagen, landing as a landmark randomized controlled trial (RCT) in The Lancet and radically shifting how every pharmacist should think about semaglutide’s role in patient care.
In a rigorously designed, 26-week, placebo-controlled trial, investigators asked a simple question: can once-weekly semaglutide (2.4 mg) help patients with both moderate-to-severe alcohol use disorder (AUD) and comorbid obesity reduce their drinking?
The answer might surprise you.
This isn’t observational data anymore
Researchers conducted this 26-week, randomised, double-blinded, placebo-controlled trial in treatment-seeking patients with moderate to severe alcohol use disorder and comorbid obesity. Participants were assigned 1:1 to receive once-weekly semaglutide 2.4 mg subcutaneously or placebo saline, alongside standard cognitive behavioural therapy.
The trial enrolled 108 adults aged 18 to 70 years with a BMI of 30 kg/m² or higher. At baseline, participants averaged 17 heavy drinking days over the preceding 30 days, and 85% met criteria for severe alcohol use disorder.
Primary endpoint:
- Semaglutide group: –41.1 percentage point reduction in heavy drinking days (95% CI, –48.7 to –33.5)
- Placebo group: –26.4 percentage points
- Between-group difference: Statistically and clinically significant
The semaglutide arm cut roughly 12 heavy drinking days per month, a 50% greater reduction than placebo. Secondary outcomes like total alcohol consumed, AUDIT scores, biomarkers, and weight also improved substantially.
Previous research hinted at GLP-1 drugs’ effects on alcohol intake, but this trial changed the game.
- Rigorous population: Treatment-seeking patients with both obesity and moderate-to-severe AUD
- Strongest signal yet: Direct, methodologically sound evidence of meaningful reduction in real-world drinking
The researchers remain cautious, rightly noting the need for larger, more diverse studies. But this is a clinical leap forward.
The brain science behind it
This isn’t just a “side effect” of the medication. GLP-1 is produced in brainstem neurons and projects into the reward circuits, the very pathways that drive alcohol’s addictive pull.
Semaglutide crosses the blood-brain barrier and acts on dopamine in the ventral tegmental area and nucleus accumbens. In plain terms, semaglutide modulates the same neural reward pathways through which alcohol exerts addictive pull.
That’s why patients on semaglutide for obesity or diabetes frequently report spontaneous reductions in drinking without being told to expect it.
These patients are already in your queue
Up to 40% of people with AUD have comorbid obesity. Many take GLP-1s for diabetes or weight management and might also drink heavily, have liver enzyme elevations, or never have been screened for AUD.
This data empowers you to screen, counsel, and address two chronic conditions at once, often using a medication patients already have in their hands.
Not FDA-approved for AUD… Yet
Semaglutide holds FDA approval for type 2 diabetes and chronic weight management. It does not hold approval for alcohol use disorder. Larger confirmatory trials in non-obese populations are necessary before regulatory submissions become realistic.
The three approved pharmacotherapies for AUD, naltrexone, acamprosate, and disulfiram, address none of the metabolic or obesity comorbidities that accompany AUD in nearly half of patients. If semaglutide gains an AUD indication, even a narrow one, it would represent a first-in-class crossover therapy. Phase 3 trials are underway but cost may limit access, particularly for patients who need it most.
5% of all deaths worldwide
Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions. The Klausen trial is the first RCT to test a GLP-1 specifically in treatment-seeking patients with AUD and it delivered a positive result in a population where 85% had severe disease.
Pharmacists who understand this data and build it into their counseling will do something rare: catch and address an addiction disorder through a medication patients are already taking, at a touchpoint those patients already trust.
Sources: The Lancet (Klausen MK et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. Lancet. 2026;407(10540):1687–1698. DOI: 10.1016/S0140-6736(26)00305-3), Healio Endocrinology, AJMC, Medscape, Conexiant, Science Media Centre, European Medical Journal, eClinicalMedicine / The Lancet (GLP-1 RA Systematic Review and Meta-Analysis, November 2025), PMC / JAMA Psychiatry (Repurposing Semaglutide for AUD, 2024), Primary Care Companion CNS Disorders (Semaglutide for AUD, January 2026)
